C S Bhugwandass1, J M A Pijnenborg2, B Pijlman3, N P M Ezendam4. 1. Department of Surgery, Slingeland Hospital, Doetinchem, Netherlands.; Gynecological Oncology Centre South, Eindhoven, Netherlands. 2. Gynecological Oncology Centre South, Eindhoven, Netherlands.; Department of Obstetrics and Gynaecology, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands. 3. Gynecological Oncology Centre South, Eindhoven, Netherlands.; Department of Obstetrics and Gynaecology, Jeroen Bosch Hospital, Den Bosch, Netherlands. 4. Gynecological Oncology Centre South, Eindhoven, Netherlands.; Centre of Research on Psychology in Somatic Diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, Netherlands.; Comprehensive Cancer Centre Netherlands, Eindhoven, Netherlands.
Abstract
BACKGROUND: There is wide variation in the application of adjuvant chemotherapy in early-stage epithelial ovarian cancer. Our aim was to assess differences in health-related quality of life (hrqol) between patients with early-stage ovarian cancer who did or did not receive chemotherapy as adjuvant treatment. METHODS: All patients diagnosed with early-stage ovarian cancer between 2000 and 2010 within the population-based Eindhoven Cancer Registry (n = 191) were enrolled in this study. Patients were requested to complete questionnaires, including the cancer-specific (qlq-C30) and ovarian cancer-specific (qlq-OV28) quality of life measures from the European Organisation for Research and Treatment of Cancer. Primary outcome measures were the generic-and cancer-specific domain scores for hrqol in ovarian cancer survivors. RESULTS: Of the 107 patients (56%) who returned the questionnaires, 57 (53.3%) had received adjuvant chemotherapy and 50 (46.7%) had been treated with surgery alone. Significant differences in hrqol between those groups were found in the symptom scales for peripheral neuropathy, attitude toward sickness, and financial situation, with worse scores in the chemotherapy group. CONCLUSIONS: Results of our study show that patients who receive adjuvant chemotherapy have a significantly worse score for 3 aspects of hrqol. Efforts should be made to reduce use of adjuvant chemotherapy in early-stage ovarian cancer. Moreover, preventive strategies to improve long-term quality of life for those who need adjuvant chemotherapy should be explored.
BACKGROUND: There is wide variation in the application of adjuvant chemotherapy in early-stage epithelial ovarian cancer. Our aim was to assess differences in health-related quality of life (hrqol) between patients with early-stage ovarian cancer who did or did not receive chemotherapy as adjuvant treatment. METHODS: All patients diagnosed with early-stage ovarian cancer between 2000 and 2010 within the population-based Eindhoven Cancer Registry (n = 191) were enrolled in this study. Patients were requested to complete questionnaires, including the cancer-specific (qlq-C30) and ovarian cancer-specific (qlq-OV28) quality of life measures from the European Organisation for Research and Treatment of Cancer. Primary outcome measures were the generic-and cancer-specific domain scores for hrqol in ovarian cancer survivors. RESULTS: Of the 107 patients (56%) who returned the questionnaires, 57 (53.3%) had received adjuvant chemotherapy and 50 (46.7%) had been treated with surgery alone. Significant differences in hrqol between those groups were found in the symptom scales for peripheral neuropathy, attitude toward sickness, and financial situation, with worse scores in the chemotherapy group. CONCLUSIONS: Results of our study show that patients who receive adjuvant chemotherapy have a significantly worse score for 3 aspects of hrqol. Efforts should be made to reduce use of adjuvant chemotherapy in early-stage ovarian cancer. Moreover, preventive strategies to improve long-term quality of life for those who need adjuvant chemotherapy should be explored.
Authors: Ellen M Lavoie Smith; Herbert Pang; Constance Cirrincione; Stewart Fleishman; Electra D Paskett; Tim Ahles; Linda R Bressler; Camilo E Fadul; Chetaye Knox; Nguyet Le-Lindqwister; Paul B Gilman; Charles L Shapiro Journal: JAMA Date: 2013-04-03 Impact factor: 56.272
Authors: Kristina L Mirabeau-Beale; Alice B Kornblith; Richard T Penson; Hang Lee; Annekathryn Goodman; Susana M Campos; Linda Duska; Lauren Pereira; Jessica Bryan; Ursula A Matulonis Journal: Gynecol Oncol Date: 2009-05-28 Impact factor: 5.482
Authors: Nicole P M Ezendam; Brenda Pijlman; Celine Bhugwandass; Johannes F M Pruijt; Floortje Mols; M Caroline Vos; Johanna M A Pijnenborg; Lonneke V van de Poll-Franse Journal: Gynecol Oncol Date: 2014-09-30 Impact factor: 5.482
Authors: J Baptist Trimbos; Mahesh Parmar; Ignace Vergote; David Guthrie; Giorgio Bolis; Nicoletta Colombo; Jan B Vermorken; Valter Torri; Constantino Mangioni; Sergio Pecorelli; Andrea Lissoni; Ann Marie Swart Journal: J Natl Cancer Inst Date: 2003-01-15 Impact factor: 13.506
Authors: F Collinson; W Qian; R Fossati; A Lissoni; C Williams; M Parmar; J Ledermann; N Colombo; A Swart Journal: Ann Oncol Date: 2014-03-14 Impact factor: 32.976
Authors: Chun-Pin Chang; Yuji Chen; Brenna Blackburn; Sarah Abdelaziz; Kerry Rowe; John Snyder; Mark Dodson; Vikrant Deshmukh; Michael Newman; Joseph B Stanford; Christina A Porucznik; Jennifer Ose; Alison Fraser; Ken Smith; Jennifer Doherty; David Gaffney; Mia Hashibe Journal: Gynecol Oncol Date: 2020-02-29 Impact factor: 5.482